Although their predicted immunogenicity scores were modest (−0.0195 for MED23 and −0.0868 for SNTB2), these values are comparable to those observed for several benchmark tumor-associated antigens, including CEA, hTERT, and TP53 (K132N). Here, TP53 is linked to neoplasm.